whitepaper
Info kit: Metabolomics in pharmaceutical research
Accelerate the discovery process of new drugs and targets with a better understanding of the metabolome and lipidome during drug development.
List view / Grid view
Proteomics
whitepaper
Application note: High-content phenotypic profiling using the cell painting assay
The cell painting assay uses up to six fluorescent dyes to label and visualize a variety of subcellular structures at the single cell level.
news
Molecular insights into LSCC may lead to new drug targets
New insights into lung squamous cell carcinoma (LSCC) have emerged from a proteogenomic study, leading to the identification of potential drug targets.
whitepaper
Application note: Measure viral-induced cytopathic effects with a quantitative luminescence assay
Depletion of ATP due to viral-induced CPE leads to a reduction in luminescence signal, enabling quantitation of viral-induced CPE in host cells.
webinar
Utilising synthetic DNA technologies for high-throughput antibody discovery and optimisation
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
news
New “atlas” charts how antibodies attack COVID-19 Spike variants
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
article
Recognition of phosphohistidine-containing peptides by antibodies
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
whitepaper
Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
article
How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
news
Anticoagulant drug a possible strategy to treat COVID-19 variants
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
news
Protein activation discovery could widen access to cancer immunotherapy
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
whitepaper
Infographic: Top reasons to select Bethyl bulk antibodies
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
whitepaper
ebook: Optimise your high value cell lines
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
whitepaper
Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
news
Structural changes in SARS-CoV-2 Alpha and Beta variants revealed
A study has uncovered previously unknown properties of the Spike protein from the SARS-CoV-2 Alpha and Beta variants.
